Sirtuin Activators for Longevity

Sirtuin Activators — scientific infographic poster

Sirtuins are a family of seven mammalian nicotinamide adenine dinucleotide-dependent deacylases (SIRT1–SIRT7) that act as master regulators of metabolism, DNA repair, and the response to nutrient stress. They were identified as longevity genes in yeast in 1999 by Leonard Guarente's lab at MIT, and the discovery that resveratrol activated yeast Sir2 and human SIRT1 ignited a fifteen-year wave of pharmaceutical and consumer interest in sirtuin-activating compounds (STACs). The story has since become more complicated — a major 2010 paper argued that the original resveratrol-SIRT1 activation was a fluorophore artifact, and a large pharmaceutical company's 2008 purchase of a biotechnology start-up developing these compounds, for $720M, was followed by the eventual shuttering of its STAC pipeline. The current evidence is more nuanced than either the boosters or the skeptics suggest: sirtuins are real longevity regulators, nicotinamide adenine dinucleotide-driven sirtuin activation is well-supported, but small-molecule allosteric activators like resveratrol and pterostilbene act on a more limited subset of substrates than originally claimed.


Table of Contents

  1. What Sirtuins Do (SIRT1–SIRT7)
  2. The Information Theory of Aging
  3. Resveratrol and the SIRT1 Activation Controversy
  4. Pterostilbene as the More Bioavailable Cousin
  5. Second-Generation STACs (SRT2104, SRT1720)
  6. Sirtuin Activation Through Substrate (Nicotinamide Adenine Dinucleotide)
  7. SIRT6 Overexpression Extends Mouse Lifespan
  8. Human Evidence for Resveratrol
  9. Practical Application and Cautions
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Sirtuins Do (SIRT1–SIRT7)

The mammalian sirtuin family has seven members with overlapping but distinct functions. They share the same catalytic core: removing acyl groups (most commonly acetyl, but also succinyl, malonyl, and others) from lysine residues on target proteins, using nicotinamide adenine dinucleotide (NAD+) as an obligate cosubstrate. Each deacylation reaction consumes one nicotinamide adenine dinucleotide molecule, which is why sirtuin activity is fundamentally constrained by nicotinamide adenine dinucleotide availability.

The seven sirtuins together affect essentially every cellular process implicated in aging — energy metabolism, DNA repair, mitochondrial function, oxidative stress response, inflammation, and chromatin maintenance. This breadth is what makes them attractive longevity targets and what makes "sirtuin activation" a marketing-friendly but technically vague claim.

Back to Table of Contents

The Information Theory of Aging

David Sinclair's 2019 book "Lifespan" and the underlying scientific papers articulate a unifying framework called the "Information Theory of Aging." The theory says that aging is primarily a loss of epigenetic information — the chromatin marks (DNA methylation, histone acetylation, histone methylation) that tell each cell which subset of its genome to express.

The Sinclair lab's ICE (inducible changes to the epigenome) mouse experiments, published in Cell in 2023, showed that repeated induction of DNA double-strand breaks (without changing the DNA sequence itself) produced an accelerated-aging phenotype in mice — gray hair, frailty, and aging changes at the physiological, cognitive and molecular levels. The paper did not report a lifespan result. Because the DNA sequence was unchanged, the mechanism was attributed to chromatin remodeling and epigenetic drift — the cells "forgot" which cell type they were.

Within this framework, sirtuins are essential because they are recruited to sites of DNA damage to facilitate repair, and the repeated relocation away from their normal chromatin sites is what drives the epigenetic drift. Nicotinamide adenine dinucleotide availability constrains sirtuin recruitment. Therefore, restoring nicotinamide adenine dinucleotide (with nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR)) and activating sirtuins (with resveratrol or pterostilbene) is theorized to slow the loss of epigenetic information.

The Information Theory is not universally accepted. Critics point out that DNA methylation clocks (Horvath, GrimAge, DunedinPACE) measure epigenetic patterns but do not prove causation — an epigenetic clock that ticks faster in stressed cells does not mean that resetting the clock would restore youth. The Sinclair lab's subsequent partial-reprogramming work (using three of the four Yamanaka factors, OSK, to reset epigenetic age in mouse retinal cells) is provocative but early. The framework is influential, but the clinical translation is mostly speculative.

Back to Table of Contents

Resveratrol and the SIRT1 Activation Controversy

Resveratrol is a stilbenoid polyphenol found in grape skins, red wine, and Japanese knotweed (the commercial source). The story begins with Howitz et al. in Nature 2003, where the Sinclair lab reported that resveratrol activated yeast Sir2 (SIRT1 homolog) and extended yeast replicative lifespan. Subsequent work in worms and flies showed similar effects, and the David Sinclair group's 2006 Nature paper (Baur et al.) reported that resveratrol improved survival and metabolic health of mice on a high-calorie diet — one of the most cited animal longevity papers of the 2000s.

The activation mechanism was reported as direct allosteric activation of SIRT1 — resveratrol binding the enzyme and increasing its substrate affinity. This finding led a large pharmaceutical company to buy, in 2008 for $720M, a biotechnology start-up built on these compounds, and to develop more potent synthetic STACs.

The trouble started in 2010 with Pacholec et al. (J Biol Chem), who showed that resveratrol's apparent SIRT1 activation in vitro was an artifact of the fluorophore-tagged peptide substrate used in standard assays. When tested against unmodified protein substrates, resveratrol showed little or no SIRT1 activation. The Pacholec paper concluded that resveratrol and the start-up's synthetic STACs (SRT2183, SRT1460, SRT1720) were not direct SIRT1 activators.

The Sinclair group's 2013 Science paper (Hubbard et al.) responded that resveratrol DOES activate SIRT1 directly, but only on a specific subset of substrates whose target lysines are flanked by hydrophobic residues. The mechanism is "assisted allosteric activation" rather than universal activation. Hubbard et al. identified PGC-1alpha and FOXO3 as substrates whose deacetylation IS accelerated by resveratrol in vivo. So both the original claim (resveratrol activates SIRT1) and the artifact critique (the original assay was misleading) turn out to be partially correct: resveratrol is a substrate-selective SIRT1 activator.

The clinical implication is that resveratrol's sirtuin-activating effect is real but more limited than the marketing implies. It may activate SIRT1 toward a small number of important substrates without globally turning on all SIRT1 activity. Whether this is clinically meaningful at the gram doses used in human trials remains uncertain.

Back to Table of Contents

Pterostilbene as the More Bioavailable Cousin

Pterostilbene is a dimethylated analog of resveratrol found in blueberries and Indian kino tree. The two structural changes — replacing two of the three hydroxyl groups with methyl ethers — dramatically alter pharmacokinetics. In a 2011 rat study that gave equal doses by mouth, about 80% of the pterostilbene dose reached the bloodstream versus about 20% of the resveratrol dose, and blood levels of pterostilbene were markedly higher (Kapetanovic et al., Cancer Chemother Pharmacol) — a result in rats, not people.

For these reasons, pterostilbene is the preferred stilbenoid in many longevity formulations. Some commercial supplements combine nicotinamide riboside with pterostilbene.

Human trial data are limited. In a 2014 randomized, double-blind, placebo-controlled trial (Riche et al., Evid Based Complement Alternat Med), 80 adults with high cholesterol took pterostilbene or placebo for 6–8 weeks. The higher dose (125 mg twice daily, 250 mg/day) lowered blood pressure (systolic −7.8 mmHg, diastolic −7.3 mmHg), but pterostilbene taken alone raised low-density lipoprotein (LDL) cholesterol by 17.1 mg/dL. The rise was not seen when pterostilbene was combined with grape extract, and it appeared smaller in people already taking cholesterol medication. The same trial's 2013 safety report (Riche et al., J Toxicol) found no harm to liver, kidney or blood-sugar markers and no significant reported side effects at up to 250 mg/day. No long-term endpoint data exist.

The comparison in short: pterostilbene reaches the bloodstream better than resveratrol in a rat study, but the only trial built to test its effect on blood pressure and cholesterol found a rise in LDL cholesterol alongside the fall in blood pressure. Two other small human studies, a 2005 study of a kino-tree extract in healthy volunteers (Hougee et al., Planta Med) and a 2025 pilot study in 30 healthy men (Otsuka et al., J Nutr Sci Vitaminol), measured blood levels and laboratory markers rather than health outcomes; both are described on the Pterostilbene page. The cost is roughly 2–3× that of resveratrol per gram, and few products contain it at meaningful doses.

Back to Table of Contents

Second-Generation STACs (SRT2104, SRT1720)

After the acquisition, the pharmaceutical pipeline focused on synthetic STACs — small molecules with greater potency and selectivity than resveratrol. The leading compounds were SRT1720, SRT2104, and SRT2183.

SRT1720 showed striking results in obese mice (Minor et al., Sci Rep 2011): improved insulin sensitivity, increased mitochondrial biogenesis, extended lifespan on high-fat diet. A 2014 mouse study (Mitchell et al., Cell Rep) found that SRT1720 also extended lifespan, delayed the onset of age-related metabolic disease and improved general health in mice fed a standard diet, with lower activity of inflammatory genes in liver and muscle. SRT2104 entered clinical trials and was studied in metabolic disease, psoriasis, and ulcerative colitis. The results were disappointing — modest or no improvement in most endpoints, and the synthetic STAC program was largely shelved.

The reasons for the clinical disappointment likely include: human SIRT1 activity may not be the rate-limiting factor for the clinical outcomes targeted; the chronic safety profile of long-term sirtuin activation in humans is unknown; and the trials used short-term endpoints in patients with established disease, which may not be where sirtuin activation would help.

The synthetic STAC story is a cautionary tale about extrapolating from rodent longevity assays to human clinical endpoints. The mechanism worked as advertised in mice; the clinical translation did not.

Back to Table of Contents

Sirtuin Activation Through Substrate (Nicotinamide Adenine Dinucleotide)

The most reliable way to increase sirtuin activity is not through allosteric activators but by raising nicotinamide adenine dinucleotide availability. Sirtuin activity is rate-limited by intracellular nicotinamide adenine dinucleotide in most conditions, especially in older tissues where nicotinamide adenine dinucleotide has declined. Raising nicotinamide adenine dinucleotide by 50% should therefore raise sirtuin activity proportionally, regardless of whether an allosteric activator is also present.

This is why the nicotinamide adenine dinucleotide (NAD) Boosters page and this page are complementary — nicotinamide adenine dinucleotide precursors provide the substrate, and stilbenoids (if they work) increase the catalytic efficiency on selected substrates. The combination, in theory, should be more effective than either alone.

Caloric restriction acts through both mechanisms simultaneously: it reduces glycolytic reduced nicotinamide adenine dinucleotide (NADH) production (raising the nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide ratio) and reduces nutrient signals that suppress sirtuin activity. This is one of the reasons caloric restriction is the strongest sirtuin activator known. The pharmaceutical longevity strategy of combining nicotinamide riboside/nicotinamide mononucleotide with resveratrol/pterostilbene is essentially trying to reproduce the caloric restriction signal without the food restriction.

Back to Table of Contents

SIRT6 Overexpression Extends Mouse Lifespan

The most striking sirtuin longevity finding outside of SIRT1 is the SIRT6 overexpression work from the Cohen lab at Bar-Ilan (Kanfi et al., Nature 2012). Transgenic male mice overexpressing SIRT6 (but not female mice) had approximately 15% extended median lifespan compared to wild-type littermates. The extension was attributed to reduced insulin-like growth factor 1 (IGF-1) signaling and improved metabolic homeostasis.

A 2021 mouse study (Roichman et al., Nat Commun) then found that extra SIRT6 reduced frailty and extended lifespan in both male and female mice. In normal mice, the liver's glucose output and blood-sugar control declined with age; old SIRT6 mice kept both, by making better use of lactate and glycerol to build glucose.

There is a human hint as well. A 2022 study (Simon et al., EMBO J) sequenced the SIRT6 gene in 450 Ashkenazi Jewish centenarians and 550 Ashkenazi Jewish people without a family history of exceptional longevity, and found a rare SIRT6 variant (two linked changes, N308K/A313S) more often in the centenarians. In cell experiments, this variant suppressed LINE1 "jumping genes" more strongly and gave stronger repair of DNA double-strand breaks than ordinary SIRT6. This is an association plus laboratory work, not proof that the variant causes long life.

SIRT6 has multiple essential functions: it deacetylates histone H3K9ac and H3K56ac at telomeres and DNA repair sites, it ADP-ribosylates PARP1 to activate DNA double-strand-break repair, and it represses glycolysis at the transcriptional level. SIRT6 deficiency in mice causes a severe progeroid phenotype with death by 4 weeks.

Small molecule SIRT6 activators are an active area of drug discovery. UBCS039 and MDL-800 are early-stage compounds with reasonable in vitro potency. None have entered clinical trials. Anthocyanins (the pigments in blueberries and dark berries) have been reported to activate SIRT6 in vitro, but the in vivo evidence is weak.

The SIRT6 story is one of the strongest pieces of evidence that sirtuin pathway manipulation can extend mammalian lifespan when done at the right point in the pathway with the right tools.

Back to Table of Contents

Human Evidence for Resveratrol

Resveratrol has been extensively studied in human trials — far more than any other STAC. The literature is large enough to draw some conclusions.

  1. Cardiovascular endpoints: a meta-analysis of six resveratrol trials with 247 people (Liu et al., Clin Nutr 2015) found no significant overall effect on systolic or diastolic blood pressure; in the trials using 150 mg/day or more, systolic pressure fell by 11.9 mmHg, while diastolic pressure did not change. The authors noted that trial results are inconsistent.
  2. Umbrella review (2026): a review of 45 systematic reviews of resveratrol trials (Sun et al., Nutr J 2026) rated four effects as high-certainty: a smaller waist (−0.80 cm), lower total cholesterol in overweight adults (−0.19 mmol/L), and lower blood pressure in people with type 2 diabetes (systolic −7.97 mmHg, diastolic −3.55 mmHg). None of the high-certainty findings concerned lifespan or aging.
  3. Diabetes: meta-analyses show modest reductions in fasting glucose and hemoglobin A1c (HbA1c) in type 2 diabetics on resveratrol. Effect size is small (~0.2% hemoglobin A1c reduction).
  4. Inflammation: variable effects on C-reactive protein (CRP) and tumor necrosis factor-alpha, generally in the direction of reduction but inconsistently.
  5. Aging biomarkers: no published trial has demonstrated epigenetic clock improvement on resveratrol.
  6. Lifespan: no human trial has reported survival data.
  7. Notable null results: the InCHIANTI cohort study (Semba et al., JAMA Intern Med 2014) tracked urinary resveratrol metabolites in 783 community-dwelling Italian older adults and found NO association between resveratrol exposure (from food) and cardiovascular events, cancer, or mortality over 9 years. This is one of the strongest pieces of evidence that dietary-level resveratrol intake (the level reached with a Western diet, from red wine, grapes and other foods) does not meaningfully extend life. The study did not measure supplements.

The honest summary on resveratrol in humans: modest biomarker effects at 250 mg–1g/day doses, no demonstrated longevity benefit, and the InCHIANTI null result showing that resveratrol at the levels reached through diet was not linked to longer life in older adults. The compound is well-tolerated and inexpensive, but the evidence for it as a longevity intervention is weak.

Back to Table of Contents

Practical Application and Cautions

What the research above means for people considering sirtuin-related supplements:

  1. Substrate versus allosteric activators: for sirtuin activity, raising nicotinamide adenine dinucleotide through nicotinamide riboside (or nicotinamide mononucleotide, with the caveats on the nicotinamide adenine dinucleotide Boosters page) is more evidence-supported than adding resveratrol on top.
  2. Pterostilbene versus resveratrol: pterostilbene reaches the blood far better in rats. The doses studied in people were 100–250 mg/day; in that trial, 250 mg/day lowered blood pressure, but pterostilbene taken alone raised LDL cholesterol by 17.1 mg/dL (see above).
  3. Caloric restriction and exercise: both raise nicotinamide adenine dinucleotide and reduce sirtuin-inhibitory signals. These are the most reliable sirtuin activators.
  4. Food sources: blueberries (pterostilbene, anthocyanins), red grapes and red wine (resveratrol), Japanese knotweed (concentrated resveratrol), parsley (apigenin, CD38 inhibitor), turmeric (curcumin, sirtuin activator at high doses).

Cautions:

Back to Table of Contents

Key Research Papers

  1. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13:2570–2580. — PubMed PMID: 10521401
  2. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001; 410:227–230. — PubMed PMID: 11242085
  3. Howitz KT et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191–196. — PubMed PMID: 12939617
  4. Hougee S et al. Selective COX-2 inhibition by a Pterocarpus marsupium extract characterized by pterostilbene, and its activity in healthy human volunteers. Planta Med 2005; 71:387–392. — PubMed PMID: 15931573
  5. Baur JA et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337–342. — PubMed PMID: 17086191
  6. Pearson KJ et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8:157–168. — PubMed PMID: 18599363
  7. Pacholec M et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285:8340–8351. — PubMed PMID: 20061378
  8. Kapetanovic IM et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 2011; 68:593–601. — PubMed PMID: 21116625
  9. Minor RK et al. SRT1720 improves survival and healthspan of obese mice. Sci Rep 2011; 1:70. — PubMed PMID: 22355589
  10. Kanfi Y et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012; 483:218–221. — PubMed PMID: 22367546
  11. Riche DM et al. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol 2013; 2013:463595. — PubMed PMID: 23431291
  12. Hubbard BP et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339:1216–1219. — PubMed PMID: 23471411
  13. Mitchell SJ et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 2014; 6:836–843. — PubMed PMID: 24582957
  14. Riche DM et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med 2014; 2014:459165. — PubMed PMID: 25057276
  15. Semba RD et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med 2014; 174:1077–1084 (InCHIANTI null result) — PubMed PMID: 24819981
  16. Liu Y et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 2015; 34:27–34. — PubMed PMID: 24731650
  17. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol 2014; 24:464–471. — PubMed PMID: 24786309
  18. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol 2016; 17:679–690. — PubMed PMID: 27552971
  19. Mostoslavsky R et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124:315–329. — PubMed PMID: 16439206
  20. Roichman A et al. Restoration of energy homeostasis by SIRT6 extends healthy lifespan. Nat Commun 2021; 12:3208. — PubMed PMID: 34050173
  21. Simon M et al. A rare human centenarian variant of SIRT6 enhances genome stability and interaction with Lamin A. EMBO J 2022; 41:e110393. — PubMed PMID: 36215696
  22. Yang JH et al. Loss of epigenetic information as a cause of mammalian aging. Cell 2023; 186:305–326.e27 (Sinclair ICE mouse) — PubMed PMID: 36638792
  23. Sun JN et al. Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutr J 2026; 25:63. — PubMed PMID: 41987155
  24. Otsuka K et al. Analysis of the effects of short-term pterostilbene intake on healthy participants: a pilot study. J Nutr Sci Vitaminol (Tokyo) 2025; 71:70–80. — PubMed PMID: 40024751

Back to Table of Contents

Connections

Back to Table of Contents